TAC1 and neoplasm: We next explored the downstream consequences of decreased neuronal excitability by examining key neuropathic sensitization markers, including CGRP (50), transient receptor potential vanilloid 1 (TRPV1) (51), and substance P (SP) (52), in tumor-bearing bones.